Abstract
Hyper-activation of nuclear factor kappa B (NF-κB) is germane to carcinogenesis by its fundamental implication in cellular de-differentiation and proliferation, the subversion of apoptosis, the promotion of neoangiogenesis, invasive growth and metastases. Conversely, the expression of multiple nuclear receptors (NRs), arbiters of cellular differentiation, decreases with progressive carcinogenesis. This review is a conceptual discussion of evidence to support NF-κB as the nexus between carcinogenesis and decreased NR expression. Furthermore, it synthesizes the thesis and antithesis of NR function in carcinogenesis and expounds on the functional antagonism between NRs and NF-κB as a basis for the chemopreventive activity of NR ligands. Finally, strategies for optimal chemopreventive interventions with NR ligands are discussed.
Keywords: functional antagonism, nuclear receptors, carcinogenesis, nuclear factor kappa b, neoangiogenesis, nr ligands
Current Cancer Drug Targets
Title: Functional Antagonism between NF-κB and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions
Volume: 4 Issue: 4
Author(s): V. B. Andela
Affiliation:
Keywords: functional antagonism, nuclear receptors, carcinogenesis, nuclear factor kappa b, neoangiogenesis, nr ligands
Abstract: Hyper-activation of nuclear factor kappa B (NF-κB) is germane to carcinogenesis by its fundamental implication in cellular de-differentiation and proliferation, the subversion of apoptosis, the promotion of neoangiogenesis, invasive growth and metastases. Conversely, the expression of multiple nuclear receptors (NRs), arbiters of cellular differentiation, decreases with progressive carcinogenesis. This review is a conceptual discussion of evidence to support NF-κB as the nexus between carcinogenesis and decreased NR expression. Furthermore, it synthesizes the thesis and antithesis of NR function in carcinogenesis and expounds on the functional antagonism between NRs and NF-κB as a basis for the chemopreventive activity of NR ligands. Finally, strategies for optimal chemopreventive interventions with NR ligands are discussed.
Export Options
About this article
Cite this article as:
Andela B. V., Functional Antagonism between NF-κB and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions, Current Cancer Drug Targets 2004; 4 (4) . https://dx.doi.org/10.2174/1568009043332952
DOI https://dx.doi.org/10.2174/1568009043332952 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Mechanisms of Colon Cancer Prevention with and Beyond COX-2 Inhibition
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Nanomedicine Impact of Immune Response on the Use of iPSCs in Disease Modeling
Current Stem Cell Research & Therapy Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
Current Cancer Drug Targets De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design RGD-based Therapy: Principles of Selectivity
Current Pharmaceutical Design Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects
Drug Design Reviews - Online (Discontinued) C-Met Inhibitors are Potential Novel Therapeutic Agents Against Listeria monocytogenes Infection Through Blocking the Bacteria Entry into Nonphagocytic Cells
Current Topics in Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics The Role of the Healthy Dietary Intake in Women with Human Papilloma Virus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Adenine Nucleotide Translocase 2, a Mitochondrial Target for Anticancer Biotherapy
Current Drug Targets The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Editorial (Thematic Issue: Targeting Transporters for CNS Drug Delivery)
Current Pharmaceutical Design Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Future of Protease Activity Assays
Current Pharmaceutical Design Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets